Abstract

The DIMI-ACCEL project aims to revolutionize integrated healthcare by introducing an innovative diagnostic framework built on Dermagnostix’ breakthrough PsorX-LabDisk technology. By fusing molecular diagnostics with digital health solutions, the project will offer unprecedented accuracy in distinguishing between psoriasis and eczema, thereby enabling personalized and cost-effective treatment pathways. In an era where healthcare systems demand seamless innovation, DIMI-ACCEL addresses the pressing need for improved decision-making in both clinical and policy settings while ensuring rapid market entry and enhanced patient access to advanced diagnostics.

The integrated approach will foster cross-sector collaboration among key European stakeholders. The project consortium combines clinical and technological expertise to establish standardized protocols, interoperable interfaces, and validated clinical pathways. Work packages are designed to cover all aspects of the project from management and clinical validation to technology development, health economic analysis, and impact assessment. The extensive clinical validation and integration work will ensure that the PsorX-LabDisk is optimally embedded within patient care routines and existing hospital IT environments, leading to improved therapeutic outcomes and healthcare efficiency.

In WP1, project management and coordination will streamline decision-making and communication between partners, ensuring compliance with EU policies and cost-effectiveness standards. WP2 will execute clinical trials and integration protocols under real-world conditions to generate high-quality evidence on the project’s added value. WP3 focuses on refining the technology, enhancing system interoperability, and facilitating the digital transformation of molecular diagnostics. WP4 will undertake comprehensive health economics and policy analyses, providing robust data to support reimbursement, market uptake, and policy alignment across EU healthcare systems. WP5, dedicated to impact assessment and dissemination, will measure project outcomes, engage end-users, and communicate results to both policymakers and the broader healthcare community.

Overall, DIMI-ACCEL is positioned to boost innovation in integrated healthcare solutions while strengthening the competitiveness of the EU health industry. By combining state-of-the-art molecular diagnostics with advanced digital integration and rigorous clinical evaluation, the project promises significant improvements in patient care, healthcare system efficiency, and evidence-based decision-making in Europe.